Biohit Oyj Press release 26.6.2019 at 14.15 local time (EEST)
Biohit Colonview® quick test is now available with a control reagent. Biohit ColonView QT Control (Cat. No. 602390) is intended as a positive quality control for BIOHIT ColonView® (Cat. No. 602 250.02). The product is an in vitro diagnostic medical device and intended to be used by healthcare professionals only.
BIOHIT ColonView is a qualitative quick test used for detecting presence of human hemoglobin (Hb) and hemoglobin/haptoglobin complex (Hb/Hp) in stool samples. The control has been designed to report a positive result on the BIOHIT ColonView cassette with the optimized concentrations of Hb and Hb/Hp.
ORDERING INFORMATION: BIOHIT ColonView QT Control Cat. No. 602390
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com